{
  "docId": "019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "docSlug": "58255c61d2bdadc3239a5fe01efc41e1",
  "documentTitle": "BioNTech | Results Presentation Deck | 43 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 43,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a numbered process flow combined with a data table to show clinical trial progression.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-5aa5-74ef-a452-60fcbf49cdc6/17",
  "deckHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "deckJsonHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6.json",
  "deckAnchorHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.92,
        "x": 0.04,
        "y": 0.4
      },
      "kind": "diagram",
      "text": "1. BNT162b2: 3rd dose Safety & immunogenicity trial; 2. BNT162b2: 3rd dose Safety & efficacy trial; 3. Beta: 3rd dose or naïve Safety & immunogenicity trial; 4. Multivalent Delta + Alpha or Delta or Alpha: 3rd dose or naïve: Safety & immunogenicity trial",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e102045-3e1d-46a5-85e2-7305c6a4e59a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.04,
        "y": 0.19
      },
      "kind": "paragraph",
      "text": "Establishing development, manufacturing and regulatory pathway for variant-specific prototype approach",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d0f5be1-2c3e-4f89-a0e8-2a43b4676f69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.92,
        "x": 0.04,
        "y": 0.6
      },
      "kind": "table",
      "text": "Study Start, Nb of participants, Boosting post dose 2, Data expected",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26af6adc-e2ce-4f93-94a5-409122c53833",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "Preemptive Strategy to Address SARS-CoV-2 Variants",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f822a42-a61a-48d6-991e-90fb56332026",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "4f300aeb-555b-4c83-ade5-ea0929e93aed",
      "evidence": "The slide contains a table/data component showing study start, number of participants, and data expected.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "a8b0f9b8-77e9-4737-847c-3f57d7327ee1",
      "evidence": "Numbered process flow showing sequential clinical trial stages.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "386d1262-e7d2-40f2-862f-00b8814ac33a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document outlines BioNTech's solutions, including its COVID-19 vaccine and pipeline development",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 25,
      "from": 15,
      "beatId": "53c149a8-57e4-41f6-bcc6-f6d3b92e5c06",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The document presents BioNTech's product portfolio, including its COVID-19 vaccine and pipeline candidates",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 42,
      "from": 7,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6afc8369-9bbf-45e1-a77c-ba4d4e30b836",
      "evidence": "The document uses the Golden Circle framework to explain its vision, strategy, and achievements",
      "position": 0,
      "objective": "To explain why BioNTech's vision and strategy are important for the future of immunotherapy",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    },
    {
      "to": 20,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "3bd35679-2871-4f13-9078-94b80c4a49b4",
      "evidence": "The document presents the potential benefits of BioNTech's solutions in addressing various diseases",
      "position": 1,
      "objective": "To highlight the potential consequences of not addressing various diseases with different therapeutic modalities",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}